PT - JOURNAL ARTICLE AU - Neumeier, Maria S. AU - Homan, Stephanie AU - Vetter, Stefan AU - Seifritz, Erich AU - Kane, John M. AU - Huhn, Maximilian AU - Leucht, Stefan AU - Homan, Philipp TI - Examining side effect variation of antipsychotic treatment in schizophrenia spectrum disorders AID - 10.1101/2020.07.27.20162727 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.27.20162727 4099 - http://medrxiv.org/content/early/2020/07/29/2020.07.27.20162727.1.short 4100 - http://medrxiv.org/content/early/2020/07/29/2020.07.27.20162727.1.full AB - Background Side effects of antipsychotic drugs play a key role in non-adherence and discontinuation of treatment in schizophrenia spectrum disorders (SSD). Precision medicine aims to minimize such side effects by selecting the right treatment for the right patient. However, to determine the extent of precision medicine that is required, we need to (1) show that there is indeed variation in side effects and (2) estimate the amount of variation in those side effects between patients. While clinical observations suggest that such variation may be considerable, a statistical comparison of side effect variation between active and control treatments is required to confirm this. Here, we hypothesized to find larger side effect variation in treatment compared with control in patients treated with first and second generation antipsychotics.Methods We included double-blind, placebo-controlled, randomized controlled trials (RCTs) of adults with a diagnosis of SSD and prescription for licensed antipsychotic drugs. Standard deviations of the pre-post treatment differences of weight gain, prolactin levels, and corrected QT (QTc) times were extracted. Data quality and validity were ensured by following the PRISMA guidelines. The outcome measure was the overall variability ratio of treatment to control across RCTs. Individual variability ratios were weighted by the inverse-variance method and entered into a random-effects model.Results We included N = 16578 patients for weight gain, N = 16633 patients for prolactin levels, and N = 10384 patients for QTc time. Variability ratios (VR) were significantly increased for weight gain (VR = 1.08; 95% CI: 1.02 - 1.14; P = 0.004) and prolactin levels (VR = 1.38; 95% CI: 1.17 - 1.62; P < 0.001) but did not reach significance for QTc time (VR = 1.05; 95% CI: 0.98 - 1.12; P = 0.135).Conclusion We found increased variability in major side effects in patients with SSD under treatment with second generation antipsychotics, suggesting that subgroups of patients or even individual patients may benefit from improved treatment allocation through stratified or personalized medicine, respectively.Competing Interest StatementIn the last 3 years Dr. Leucht has received honoraria for service as a consultant or adviser and/or for lectures from Angelini, Boehringer Ingelheim, Geodon and Richter, Janssen, Johnson and Johnson, Lundbeck, LTS Lohmann, MSD, Otsuka,Recordati, SanofiAventis, Sandoz, Sunovion, TEVA. Dr. Kane reported grants from Otsuka, Lundbeck and Janssen, as well as other from Alkermes, Allergan, Forum, Genentech, Lundbeck, Intracellular Therapies, Janssen, Johnson and Johnson, Merck, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, Teva, Vanguard Research Group, and LB Pharmaceuticals outside of the submitted work. No other disclosures were reported.Funding StatementPH is supported by a NARSAD grant from the Brain & Behavior Research Foundation (28445) and by a Research Grant from the Novartis Foundation (20A058).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A, meta-analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code are freely available online to ensure reproducibility at https://github.com/homanlab/sideeffects/.